The Panbio COVID-19 Ag Rapid Test: Which Performances are for COVID-19 Diagnosis?
Journal
Clinical laboratory
ISSN: 1433-6510
Titre abrégé: Clin Lab
Pays: Germany
ID NLM: 9705611
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
16
11
2021
Statut:
ppublish
Résumé
Rapid antigen detection assays are promising tools for the diagnosis of COVID-19. We assess the performances of the Panbio COVID-19 Ag Rapid Test. The Panbio COVID-19 Ag Rapid test was compared to a reference RT-PCR performed on the same nasopharyngeal swab (NPS). Overall, 81 NPS were tested retrospectively and 330 healthcare workers (HCWs) were tested prospectively. Retrospective analyze. Of the 48 SARS-CoV-2 positive NPS, 19 (39.6%) were found positive with the Panbio COVID-19. There was no cross-reactivity with SARS-CoV-2 negative NPS. The Kappa value was 0.459. Prospective analyze. The prevalence of COVID-19 was 26.1% in symptomatic HCWs. The overall sensitivity and specificity of the Panbio COVID-19 were 47.2% and 100.0% respectively. The sensitivity was 55.2% and 14.3% in those tested within and after 4 days of diseases respectively. The Panbio COVID-19 Ag Rapid test displays low performance for the identification of SARS-CoV-2 infected patients.
Sections du résumé
BACKGROUND
BACKGROUND
Rapid antigen detection assays are promising tools for the diagnosis of COVID-19. We assess the performances of the Panbio COVID-19 Ag Rapid Test.
METHODS
METHODS
The Panbio COVID-19 Ag Rapid test was compared to a reference RT-PCR performed on the same nasopharyngeal swab (NPS). Overall, 81 NPS were tested retrospectively and 330 healthcare workers (HCWs) were tested prospectively.
RESULTS
RESULTS
Retrospective analyze. Of the 48 SARS-CoV-2 positive NPS, 19 (39.6%) were found positive with the Panbio COVID-19. There was no cross-reactivity with SARS-CoV-2 negative NPS. The Kappa value was 0.459. Prospective analyze. The prevalence of COVID-19 was 26.1% in symptomatic HCWs. The overall sensitivity and specificity of the Panbio COVID-19 were 47.2% and 100.0% respectively. The sensitivity was 55.2% and 14.3% in those tested within and after 4 days of diseases respectively.
CONCLUSIONS
CONCLUSIONS
The Panbio COVID-19 Ag Rapid test displays low performance for the identification of SARS-CoV-2 infected patients.
Identifiants
pubmed: 34758228
doi: 10.7754/Clin.Lab.2021.210304
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM